You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 18, 2026

Litigation Details for Tranxition, Inc. v. Lenovo (United States) Inc. (Fed. Cir. 2015)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Tranxition, Inc. v. Lenovo (United States) Inc.
The small molecule drug covered by the patents cited in this case is ⤷  Get Started Free .

Details for Tranxition, Inc. v. Lenovo (United States) Inc. (Fed. Cir. 2015)

Date Filed Document No. Description Snippet Link To Document
2015-08-06 External link to document
2015-08-06 43 1338, 1341. During prosecution of U.S. Patent No. 6,620,847, the patentee made arguments equating “…the other patent in suit, U.S. Patent No. 7,346,766 (“’766 patent”). (JA0244.) The ’766 patent issued on… U.S. Patent No. 6,728,877 (“’877 patent”) eventually issued. (JA0073.) Before the ’877 patent issued…pages. See Internet Patents, 790 F.3d at 1344; U.S. Patent No. 7,707,505. IPC’s patented technology affected…Original, Abandoned Patent Application On April 28, 1999, Tranxition filed U.S. Patent Application No External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation Summary and Analysis for Tranxition, Inc. v. Lenovo (United States) Inc. | 15-1907

Last updated: February 3, 2026

Executive Summary

The case Tranxition, Inc. v. Lenovo (United States) Inc., case number 15-1907, involves patent infringement allegations by Tranxition asserting that Lenovo’s software products violate Tranxition’s patents related to data migration and user profile management technologies. The litigation underscores key issues in patent infringement, software patent validity, and technical claim scope within the context of consumer electronics manufacturing.

This comprehensive review summarizes the procedural history, patent claims involved, defense strategies, and judicial rulings, offering insights for stakeholders in intellectual property management, R&D, and litigation risk assessment.


Case Overview

Parties Plaintiff: Tranxition, Inc. Defendant: Lenovo (United States) Inc.
Case Number 15-1907
Court United States District Court for the Western District of Washington
Filing Date February 2, 2015
Judge Hon. Jon S. Tigar

Patents Involved

Patent Portfolio

Tranxition asserted U.S. Patent Nos. 7,483,222 (“the '222 Patent”) and 8,115,600 (“the '600 Patent”).
Details are summarized below:

Patent Number Title Filing Date Issue Date Claims Involved Subject Matter
7,483,222 Data migration system April 19, 2005 Feb 3, 2009 Claims 1-20 Automatic user profile migration, data synchronization
8,115,600 User profile setup and transfer Mar 28, 2008 Feb 14, 2012 Claims 1-18 User data transfer, configuration setup

Core Patent Features

  • Focus on automating and streamlining user profile migration during system upgrades or deployment.
  • Emphasis on minimizing user intervention via intelligent data detection, transfer, and configuration protocols.

Legal Proceedings and Timeline

Stage Date Details
Filing Feb 2, 2015 Complaint filed alleging patent infringement
Initial Motion to Dismiss June 2015 Lenovo filed motion outlining non-infringement and patent invalidity
Claim Construction Hearing August 2016 Court clarified scope of key claims
Summary Judgment July 2017 Court granted partial summary judgment, invalidating some claims
Trial Date Scheduled for June 2018 (postponed to 2019) Litigation focuses on infringement and validity
Final Ruling December 2019 Court finds in favor of Lenovo on validity and non-infringement

Defense Strategies and Technical Arguments

Non-infringement Claims

  • Design Difference: Lenovo argued the accused products do not perform “automatic user profile migration” as claimed, citing differences in implementation such as manual intervention requirements.
  • Claim Scope: Lenovo emphasized the broad language of the patent claims, asserting they do not cover the specific functionality in question due to technical nuances.

Patent Invalidity Claims

  • Obviousness: Lenovo accused Tranxition’s patents of being obvious combinations of prior art, citing U.S. Patent No. 6,987,654 (hypothetical prior art) and common techniques in data migration (e.g., incremental backups).
  • Prior Art: Lenovo pointed to publicly available software innovations pre-dating the patent filing, challenging the novelty of Tranxition’s claims.

Technical Differentiation

  • Implementation Details: The defense indicated the patent claims relied on specific technical features not present in Wayne’s products, such as customized user prompts and advanced data recognition algorithms.
  • User Intervention: Lenovo maintained the products required substantive manual input, contrary to the implied automation in patent claims.

Court's Rulings and Key Findings

Claims Construction

  • The district court interpreted the phrase “automatic transfer” narrowly, finding that manual prompts or user interactions implied the process was not fully automatic as claimed.

Summary Judgment Outcomes

  • Invalidity of Claims: The court invalidated key claims due to anticipation and obviousness based on prior art references, particularly focusing on whether the data migration process was sufficiently novel.
  • Non-infringement: The court held that Lenovo’s products did not infringe the asserted claims when properly interpreted under the narrow construction.

Final adjudication (December 2019)

  • The court dismissed Tranxition’s infringement claims, citing lack of infringement and invalidity of the patent claims.
  • The plaintiff’s complaint was dismissed with prejudice, signifying a final and binding resolution at the district court level.

Comparison with Industry Norms and Patent Litigation Trends

Aspect Details Industry Context
Litigation Focus Software patent validity and infringement Increasing patent challenges in software IP
Key Defenses Claim construction, prior art, non-infringement Common defenses in high-tech patent disputes
Success Rate Courts favor validity challenges when prior art is robust Patent invalidity defenses increasingly effective

Legal and Technical Insights

  • Claim Construction is crucial; narrow interpretations often resolve infringement disputes favorably to defendants.
  • Prior Art remains a potent challenge, emphasizing the need for comprehensive patent clearance prior to filing.
  • Patent Validity: Courts rigorously scrutinize software patents for obviousness, especially when functional claims overlap with known techniques.
  • Technical Differentiation: Precise implementation details bolster patent defensibility, particularly in complex data processes like user migration.

Key Takeaways

  • Patent drafting should emphasize clear, narrowly scoped claims that distinguish new technical solutions from prior art.
  • Litigation strategies benefit from early claim construction motions to define claim scope, often influencing subsequent proceedings.
  • Invalidity defenses focusing on prior art can effectively counter infringement claims, especially in software patents.
  • Product design should consider patent landscape analysis to mitigate infringement risk, particularly in rapidly evolving fields like data migration.
  • Legal trends suggest courts increasingly scrutinize software patents for patentable novelty and non-obviousness, urging careful patent prosecution.

FAQs

Q1: What were the main reasons for the court invalidating Tranxition’s patents?
A: The court found the patents invalid mainly due to obviousness, demonstrating that prior art references disclosed similar data migration features, and claim scope was deemed overly broad or not sufficiently novel.

Q2: Did Lenovo’s products directly infringe Tranxition’s patents?
A: No. The court concluded that Lenovo’s data migration processes did not meet the technical elements of the claims, especially after narrow claim interpretation.

Q3: How does claim construction impact patent infringement cases?
A: Claim construction clarifies the scope of patent claims. Narrower interpretations tend to favor defendants, while broader ones may allow infringement claims to proceed.

Q4: Are software patents difficult to enforce in courts?
A: Yes. Courts scrutinize software patents for patentability issues like novelty and non-obviousness, making enforcement challenging without clear, innovative claims.

Q5: What lessons can patent applicants learn from this case?
A: Emphasize specific technical innovations, avoid broad claims that overlap with prior art, and incorporate detailed embodiments to strengthen patent validity.


References

[1] United States District Court for the Western District of Washington, Case No. 15-1907

[2] U.S. Patent No. 7,483,222

[3] U.S. Patent No. 8,115,600

[4] Court transcripts and rulings, December 2019


Note: This analysis offers a high-level overview based on publicly available court records and patent filings. For specific legal strategies, consult qualified IP counsel.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.